for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cogent Biosciences Inc

COGT.OQ

Latest Trade

10.24USD

Change

0.38(+3.85%)

Volume

42,228

Today's Range

9.76

 - 

10.44

52 Week Range

1.18

 - 

14.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.86
Open
9.85
Volume
42,228
3M AVG Volume
3.52
Today's High
10.44
Today's Low
9.76
52 Week High
14.88
52 Week Low
1.18
Shares Out (MIL)
11.34
Market Cap (MIL)
116.15
Forward P/E
-18.96
Dividend (Yield %)
--

Next Event

Unum Therapeutics Inc Annual Shareholders Meeting

Latest Developments

More

Cogent Biosciences Inc Says Majority Of Patients Treated With PLX9486, Sunitinib Experienced Clinical Benefit With A Median PFS Of 12 Months, 20% ORR

Cogent Biosciences Reports Third Quarter 2020 Financial Results And Provides Corporate Updates

Cogent Biosciences Appoints Andrew Robbins As Chief Executive Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cogent Biosciences Inc

Cogent Biosciences, Inc., formerly Unum Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing precision therapies for genetically defined diseases. The Company also engaged in developing curative cell therapies for solid tumors. Its proprietary technology includes bolt-on chimeric receptor (BOXR), designed to overcome resistance of the solid tumor microenvironment (TME) to T cell attack. The Company also developed product candidates using its proprietary technology, antibody-coupled T cell receptor (ACTR), an autologous engineered T-cell therapy that combines the cell-killing ability of T cells and the tumor-targeting ability. Its preclinical program offers, BOXR1030, for the treatment of solid tumor cancers and PLX9486, is a tyrosine kinase inhibitor that is designed to inhibit the KIT D816V mutation as well as other mutations in KIT exon 17 to treat systemic mastocytosis and gastrointestinal stromal tumors (GIST) patients.

Industry

Biotechnology & Drugs

Contact Info

200 CAMBRIDGE PARK DRIVE, SUITE 3100

CAMBRIDGE, MA

02140

United States

+1.617.9455576

https://www.unumrx.com/

Executive Leadership

Andrew R. Robbins

President, Chief Executive Officer and Principal Executive Officer, Director

John L. Green

Chief Financial Officer, Vice President - Finance, Controller

Jessica Sachs

Chief Medical Officer

Chris W. Cain

Director

Peter Harwin

Director

Key Stats

1.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-5.560

2019

-4.160

2020(E)

-4.497
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.02
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-79.86
Return on Equity (TTM)
-61.87

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up